Molbio Diagnostics IPO
Molbio Diagnostics is an innovative point-of-care (POC) diagnostics company that develops affordable, rapid, and accurate diagnostic solutions for infectious and non-communicable diseases. Its flagship product, Truenat, is a portable, battery-powered PCR testing platform that delivers results within an hour. Designed for use in resource-limited settings, it enables quick and decentralised disease diagnosis at the point of care.
IPO GMP
+₹116
+14% expected gain
Price Band
₹768 - ₹807
Lot Size
18 shares
Min Investment
₹14,526
Listing Date
August 17, 2026
About Molbio Diagnostics
Company overview, business, and key facts.
Molbio Diagnostics is an innovative point-of-care (POC) diagnostics company that develops affordable, rapid, and accurate diagnostic solutions for infectious and non-communicable diseases. Its flagship product, Truenat, is a portable, battery-powered PCR testing platform that delivers results within an hour. Designed for use in resource-limited settings, it enables quick and decentralised disease diagnosis at the point of care.
Through its wholly owned subsidiary, Bigtec Labs, Molbio has strong research and development capabilities focused on creating diagnostic platforms for point-of-care (POC) testing. From product development to large-scale deployment, the company aims to improve access to reliable and affordable healthcare for everyone.
Headquarters
South Goa, Goa
Promoters
Chandrasekhar Bhaskaran Nair, Exxora Trading LLP, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram, Sriram Natarajan
Website
http://www.molbiodiagnostics.com/
IPO Details
Subscription Status
How many times each investor category has bid for the issue.
Strengths & Risks
Strengths
- Strong Position in Molecular Diagnostics: Favorably placed to take advantage of the emerging molecular diagnostics market owing to its Truenat point-of-care diagnostics platform.
- Innovation & R&D Capability: Good innovation and research & development capacity demonstrated by past successful development of innovative diagnostic products.
- Innovative Point-of-Care Platform: Has developed and commercialized its proprietary Truenat point-of-care molecular diagnostics platform based on PCR.
Risks
- R&D & Regulatory Approval Risk: The company is dependent on effective research and development and regulatory approval of new diagnostic tests.
- Variable Sales Demand: Variable sales cycle makes it difficult to predict revenues and performance of the company.
- Demand Forecasting & Stock Management Risk: The inability to forecast and manage inventories correctly may result in excessive inventory or shortage thereof.
Financials
Restated summary financials for the most recent periods.
Figures are indicative and restated for presentation.
Molbio Diagnostics IPO Key Numbers
Calculated by IPOLyst from the published offer-document data. These are figures, not buy or sell calls.
Market cap at upper band
₹9,299.9 Cr
Post-IPO shares × upper price band
P/E on 2026 profit
56.7x
Peer median 63x (discount of 10%)
Price to sales
6.39x
Revenue growth, 2026
+41.6%
31.6% a year over the period
Profit growth, 2026
+18.4%
40.2% a year over the period
Profit margin (PAT)
11.3%
EBITDA margin 22.56%
ROE / ROCE
15.59% / 17.55%
As published in the offer document
Promoter holding
46.65% → 37.69%
Before → after the IPO
Issue mix
21.3% fresh / 78.7% sale
Fresh issue goes to the company, offer for sale to selling shareholders
GMP-implied gain per lot
₹2,088
18 shares on ₹14,526. GMP is unofficial.
Watch-outs
- 78.7% of the issue is an offer for sale, so most money goes to selling shareholders, not the company.
- 1 use-of-proceeds item(s) have no disclosed amount.
- Promoter holding drops to 37.69% after the IPO.
Scenarios apply today's grey market premium figures to the upper price band. They are illustrations, not predictions. GMP is unofficial and can be wrong.
IPO Analysis SummaryAI-generated
A plain-language review of Molbio Diagnostics's financials, valuation and demand, based only on the verified figures above. For information only. It does not recommend whether to apply.
Molbio Diagnostics IPO Review
Analysis based on live GMP, subscription, and issue details.
As of today, Molbio Diagnostics IPO is trading at a grey market premium (GMP) of +₹116 (+14% estimated listing gain), indicating positive market sentiment.
The IPO has been subscribed 70.26x overall — QIB: 186.39x, NII: 49.8x, Retail: 12.96x.
Molbio Diagnostics IPO subscription has closed. The shares are expected to list on August 17, 2026.
The minimum investment required is ₹14,526 for 18 shares (1 lot). Retail investors can apply at cut-off price for the best chance of allotment.
Key strengths include: Strong Position in Molecular Diagnostics: Favorably placed to take advantage of the emerging molecular diagnostics market owing to its Truenat point-of-care diagnostics platform.; Innovation & R&D Capability: Good innovation and research & development capacity demonstrated by past successful development of innovative diagnostic products.. Investors should note the following risks: R&D & Regulatory Approval Risk: The company is dependent on effective research and development and regulatory approval of new diagnostic tests.; Variable Sales Demand: Variable sales cycle makes it difficult to predict revenues and performance of the company..
Disclaimer: IPO GMP is indicative and sourced from the grey market. This is not investment advice. Please consult a SEBI-registered advisor before investing.
Molbio Diagnostics IPO — Frequently Asked Questions
What is Molbio Diagnostics IPO GMP today?
Molbio Diagnostics IPO GMP (grey market premium) today is +₹116, suggesting an estimated listing gain of +14%. GMP is indicative and subject to change.
What is the price band of Molbio Diagnostics IPO?
The price band for Molbio Diagnostics IPO is ₹768 - ₹807 with a lot size of 18 shares. The minimum investment required is ₹14,526.
When is Molbio Diagnostics IPO allotment date?
Molbio Diagnostics IPO allotment is expected to be finalised on August 13, 2026. You can check your allotment status on the registrar's website (Kfin Technologies Ltd.) using your PAN number.
When will Molbio Diagnostics IPO list on NSE/BSE?
Molbio Diagnostics IPO is expected to list on BSE, NSE on August 17, 2026.
How to check Molbio Diagnostics IPO allotment status?
To check Molbio Diagnostics IPO allotment status, visit the registrar's website (Kfin Technologies Ltd.) and enter your PAN number, application number, or DP/Client ID. You can also check on the BSE IPO allotment page at https://www.bseindia.com/investors/appli_check.aspx.
Should I apply for Molbio Diagnostics IPO?
Molbio Diagnostics IPO is showing a strong GMP of +₹116 (+14%), indicating positive market sentiment for listing gains. However, GMP is informal and not a guarantee of returns. Evaluate the company's fundamentals, price band, and your own risk appetite before applying. IPOLyst is not a SEBI-registered investment advisor — please do your own research.
What is the lot size of Molbio Diagnostics IPO?
The lot size for Molbio Diagnostics IPO is 18 shares per lot. The minimum investment for retail investors is ₹14,526. Retail investors can apply for a maximum of 13 lots or up to ₹2 lakh, whichever is lower.